|
1
|
A prognostic score for patients with lower risk myelodysplastic syndrome.
|
Leukemia
|
2007
|
3.45
|
|
2
|
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
|
Blood
|
1997
|
3.14
|
|
3
|
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
|
J Clin Oncol
|
2001
|
2.71
|
|
4
|
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
|
Leukemia
|
2003
|
2.60
|
|
5
|
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
|
Blood
|
2000
|
2.53
|
|
6
|
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
|
J Clin Invest
|
2001
|
2.21
|
|
7
|
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
|
N Engl J Med
|
1994
|
2.09
|
|
8
|
Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia.
|
Blood
|
1992
|
2.00
|
|
9
|
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
|
Blood
|
1998
|
1.91
|
|
10
|
Therapeutic response in phase I trials of antineoplastic agents.
|
Cancer Treat Rep
|
1986
|
1.91
|
|
11
|
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
|
Blood
|
1993
|
1.82
|
|
12
|
Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia.
|
Leukemia
|
1997
|
1.73
|
|
13
|
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
|
Blood
|
1999
|
1.57
|
|
14
|
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.
|
J Clin Oncol
|
2000
|
1.53
|
|
15
|
Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.
|
Leukemia
|
2001
|
1.44
|
|
16
|
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
|
Leukemia
|
2005
|
1.44
|
|
17
|
Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.
|
Am J Med
|
1992
|
1.41
|
|
18
|
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
|
J Clin Oncol
|
1993
|
1.38
|
|
19
|
Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature.
|
J Clin Oncol
|
1993
|
1.23
|
|
20
|
A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.
|
Blood
|
1996
|
1.17
|
|
21
|
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents.
|
Clin Cancer Res
|
1996
|
1.17
|
|
22
|
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
|
Leukemia
|
2002
|
1.14
|
|
23
|
Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL).
|
Leukemia
|
2002
|
1.10
|
|
24
|
Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.
|
Blood
|
1997
|
1.10
|
|
25
|
Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.
|
Leukemia
|
1995
|
1.08
|
|
26
|
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
|
Clin Cancer Res
|
1999
|
1.08
|
|
27
|
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
|
Cancer Res
|
1987
|
1.08
|
|
28
|
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.
|
Leuk Lymphoma
|
2001
|
1.06
|
|
29
|
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
|
Blood
|
1996
|
1.06
|
|
30
|
Response to salvage therapy and survival after relapse in acute myelogenous leukemia.
|
J Clin Oncol
|
1989
|
1.04
|
|
31
|
Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above.
|
Br J Haematol
|
1996
|
1.04
|
|
32
|
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
|
Cancer
|
2000
|
1.03
|
|
33
|
Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
|
Semin Oncol
|
1987
|
1.02
|
|
34
|
Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells.
|
Oncogene
|
1992
|
1.01
|
|
35
|
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
|
Blood
|
1993
|
1.01
|
|
36
|
Treatment of parkinson's disease with bromocriptine.
|
N Engl J Med
|
1976
|
1.00
|
|
37
|
Cerebral arteritis in scleroderma.
|
Stroke
|
1980
|
0.98
|
|
38
|
Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites.
|
Int J Radiat Oncol Biol Phys
|
1986
|
0.98
|
|
39
|
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
|
Semin Oncol
|
1993
|
0.96
|
|
40
|
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
|
Ann Hematol
|
2004
|
0.96
|
|
41
|
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
|
Leuk Lymphoma
|
1993
|
0.95
|
|
42
|
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
|
Blood
|
1991
|
0.95
|
|
43
|
Granulocytic sarcoma of the pancreas: a report of two cases and literature review.
|
Clin Lab Haematol
|
1999
|
0.95
|
|
44
|
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.
|
Am J Med
|
1998
|
0.95
|
|
45
|
Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia.
|
Blood
|
1994
|
0.94
|
|
46
|
Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
|
Leukemia
|
2003
|
0.94
|
|
47
|
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
|
Clin Cancer Res
|
1995
|
0.94
|
|
48
|
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Blood
|
1996
|
0.93
|
|
49
|
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
|
Cancer
|
2001
|
0.93
|
|
50
|
Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
|
Leukemia
|
1995
|
0.92
|
|
51
|
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.
|
Cancer
|
1994
|
0.91
|
|
52
|
NCCN Practice Guidelines for Acute Myelogenous Leukemia.
|
Oncology (Williston Park)
|
2000
|
0.91
|
|
53
|
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors.
|
Leukemia
|
2002
|
0.90
|
|
54
|
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
|
Leukemia
|
2001
|
0.90
|
|
55
|
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
|
J Clin Oncol
|
1999
|
0.89
|
|
56
|
Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts.
|
Cancer Res
|
1987
|
0.89
|
|
57
|
CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?
|
J Clin Oncol
|
1999
|
0.88
|
|
58
|
Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.
|
Leuk Lymphoma
|
2001
|
0.88
|
|
59
|
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.
|
Blood
|
1992
|
0.88
|
|
60
|
Phase I study of liposomal daunorubicin in patients with acute leukemia.
|
Invest New Drugs
|
1999
|
0.87
|
|
61
|
Pharmacologically directed ara-C therapy for refractory leukemia.
|
Semin Oncol
|
1985
|
0.87
|
|
62
|
Increased CD38 expression is associated with favorable prognosis in adult acute leukemia.
|
Leuk Res
|
2000
|
0.86
|
|
63
|
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
|
Am J Med
|
1993
|
0.86
|
|
64
|
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
|
Leukemia
|
2003
|
0.86
|
|
65
|
Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
|
Leukemia
|
1994
|
0.86
|
|
66
|
Cytomegalovirus pneumonia in adults with leukemia: an emerging problem.
|
Clin Infect Dis
|
2001
|
0.86
|
|
67
|
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
|
J Clin Oncol
|
1997
|
0.86
|
|
68
|
The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reaction.
|
Blood
|
1992
|
0.85
|
|
69
|
Targeted therapy of AML new concepts.
|
Ann Hematol
|
2004
|
0.85
|
|
70
|
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
|
J Clin Oncol
|
1993
|
0.85
|
|
71
|
Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
|
Leuk Res
|
1995
|
0.85
|
|
72
|
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine.
|
Ann Intern Med
|
1993
|
0.85
|
|
73
|
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
|
Leukemia
|
1993
|
0.84
|
|
74
|
Bromocriptine in Parkinson disease: further studies.
|
Neurology
|
1979
|
0.84
|
|
75
|
All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
|
Cancer
|
1994
|
0.84
|
|
76
|
Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
|
Clin Cancer Res
|
1997
|
0.84
|
|
77
|
The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).
|
Biochem Biophys Res Commun
|
1986
|
0.84
|
|
78
|
Second cancer risk in hairy cell leukemia: analysis of 350 patients.
|
J Clin Oncol
|
1997
|
0.84
|
|
79
|
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
|
Leukemia
|
1996
|
0.83
|
|
80
|
Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid.
|
Blood
|
2001
|
0.83
|
|
81
|
Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia.
|
Blood
|
2000
|
0.83
|
|
82
|
Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia.
|
Leuk Res
|
1999
|
0.82
|
|
83
|
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
|
Cancer
|
1993
|
0.82
|
|
84
|
Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia.
|
Cancer Res
|
1992
|
0.82
|
|
85
|
Lergotrile in Parkinson disease: further studies.
|
Neurology
|
1979
|
0.82
|
|
86
|
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
|
Leukemia
|
2002
|
0.82
|
|
87
|
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
|
Leukemia
|
1997
|
0.81
|
|
88
|
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
|
Invest New Drugs
|
1999
|
0.81
|
|
89
|
Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome.
|
Br J Haematol
|
2001
|
0.81
|
|
90
|
Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults.
|
Leukemia
|
2002
|
0.81
|
|
91
|
Fludarabine phosphate: a new active agent in hematologic malignancies.
|
Semin Hematol
|
1994
|
0.81
|
|
92
|
Decitabine studies in chronic and acute myelogenous leukemia.
|
Leukemia
|
1997
|
0.81
|
|
93
|
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
|
Exp Hematol
|
1993
|
0.81
|
|
94
|
Application of the International Scoring System for myelodysplasia to M.D. Anderson patients.
|
Blood
|
1997
|
0.81
|
|
95
|
Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two.
|
Arch Intern Med
|
1984
|
0.81
|
|
96
|
An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients.
|
J Antimicrob Chemother
|
1993
|
0.80
|
|
97
|
Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha.
|
Leukemia
|
1994
|
0.80
|
|
98
|
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
|
Clin Cancer Res
|
1997
|
0.80
|
|
99
|
Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
|
Leuk Res
|
2006
|
0.80
|
|
100
|
Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
|
Leukemia
|
1994
|
0.80
|
|
101
|
Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
|
J Clin Oncol
|
1994
|
0.79
|
|
102
|
Comparison of acute myeloid leukemia patients at MD Anderson: 1982-1986 vs 1992-1996.
|
Leukemia
|
1997
|
0.79
|
|
103
|
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
|
Leuk Lymphoma
|
1998
|
0.79
|
|
104
|
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
|
Leukemia
|
2007
|
0.79
|
|
105
|
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
|
Leukemia
|
1997
|
0.78
|
|
106
|
Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
|
J Clin Oncol
|
1989
|
0.78
|
|
107
|
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
|
Leuk Lymphoma
|
2000
|
0.78
|
|
108
|
Clinical experience with fludarabine in hemato-oncology.
|
Hematol Cell Ther
|
1996
|
0.78
|
|
109
|
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.
|
Blood
|
1994
|
0.78
|
|
110
|
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
|
Cancer
|
1993
|
0.78
|
|
111
|
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
|
Ann Oncol
|
1999
|
0.78
|
|
112
|
Irreversible pulmonary toxicity after single course of BCNU.
|
Am J Med Sci
|
1980
|
0.77
|
|
113
|
High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
|
Leuk Lymphoma
|
2001
|
0.77
|
|
114
|
Modulation of arabinosylcytosine metabolism during leukemia therapy.
|
Adv Exp Med Biol
|
1994
|
0.77
|
|
115
|
Topoisomerase II as a target of antileukemic drugs.
|
NCI Monogr
|
1987
|
0.77
|
|
116
|
A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Leukemia
|
1997
|
0.77
|
|
117
|
Clinical experience with fludarabine in leukaemia.
|
Drugs
|
1994
|
0.77
|
|
118
|
Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
|
Clin Cancer Res
|
1998
|
0.76
|
|
119
|
Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia.
|
Leukemia
|
2006
|
0.76
|
|
120
|
The short form of PML-RARalpha fusion transcript is associated with poor survival.
|
Leuk Res
|
1999
|
0.76
|
|
121
|
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
|
Leuk Lymphoma
|
1993
|
0.76
|
|
122
|
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
|
Clin Cancer Res
|
1997
|
0.75
|
|
123
|
Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy.
|
Hematol Pathol
|
1994
|
0.75
|
|
124
|
Treatment of acute myelogenous leukemia.
|
N Engl J Med
|
1995
|
0.75
|
|
125
|
Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
|
Cancer
|
1991
|
0.75
|
|
126
|
Acute myeloid leukemia-type chemotherapy for myelodysplasia.
|
J Clin Oncol
|
1996
|
0.75
|
|
127
|
Response from Estey to X Thomas et al.
|
Leukemia
|
1998
|
0.75
|
|
128
|
Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia.
|
Semin Oncol
|
1987
|
0.75
|
|
129
|
Pharmacologically directed design of leukemia therapy.
|
Haematol Blood Transfus
|
1990
|
0.75
|
|
130
|
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
|
Cytokines Mol Ther
|
1995
|
0.75
|
|
131
|
Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.
|
Semin Hematol
|
1990
|
0.75
|
|
132
|
Premature chromosome condensation in the study of minimal residual disease.
|
Bone Marrow Transplant
|
1990
|
0.75
|
|
133
|
Treatment of Parkinson's disease with lergotrile mesylate.
|
JAMA
|
1977
|
0.75
|
|
134
|
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
|
Leukemia
|
1992
|
0.75
|
|
135
|
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
|
Leuk Lymphoma
|
1999
|
0.75
|
|
136
|
Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance.
|
Leukemia
|
1995
|
0.75
|
|
137
|
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
|
Leuk Lymphoma
|
1995
|
0.75
|
|
138
|
Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4.
|
Leuk Res
|
1997
|
0.75
|
|
139
|
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
|
Leuk Lymphoma
|
1993
|
0.75
|
|
140
|
Lergotrile in Parkinson's disease.
|
Lancet
|
1976
|
0.75
|
|
141
|
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
|
Biochem Pharmacol
|
1987
|
0.75
|
|
142
|
Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
|
Neurology
|
1978
|
0.75
|
|
143
|
Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
|
Leukemia
|
1991
|
0.75
|
|
144
|
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
|
Cancer
|
1999
|
0.75
|
|
145
|
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
|
Invest New Drugs
|
2001
|
0.75
|
|
146
|
Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor.
|
Invest New Drugs
|
1985
|
0.75
|
|
147
|
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
1993
|
0.75
|
|
148
|
What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?
|
Am J Med
|
1994
|
0.75
|
|
149
|
High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission.
|
Cancer
|
1990
|
0.75
|
|
150
|
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
|
Semin Oncol
|
1985
|
0.75
|
|
151
|
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
|
Leuk Lymphoma
|
1998
|
0.75
|
|
152
|
When is selection bias not selection bias.
|
Am J Hematol
|
1996
|
0.75
|
|
153
|
Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy.
|
Blood
|
1999
|
0.75
|
|
154
|
Topotecan in chronic lymphocytic leukemia.
|
Cancer
|
1995
|
0.75
|
|
155
|
High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
|
J Clin Oncol
|
1986
|
0.75
|
|
156
|
Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.
|
Clin Cancer Res
|
1998
|
0.75
|
|
157
|
Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain.
|
Cancer
|
1995
|
0.75
|
|
158
|
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
|
Cancer Res
|
1991
|
0.75
|
|
159
|
Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia.
|
Haematol Blood Transfus
|
1990
|
0.75
|
|
160
|
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
|
Acta Haematol
|
1987
|
0.75
|
|
161
|
Highly reproducible detection and semi-quantification of telomerase activity.
|
Biotechniques
|
2001
|
0.75
|
|
162
|
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
|
Leukemia
|
2017
|
0.75
|